AtriCure (ATRC) Stock Price, News & Analysis

Company Overview

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Key Stats

• Today's Range: $35.66 to $36.98
• 50-Day Range: $29.24 to $37.54
• 52-Week Range: $20.20 to $43.11
• Volume: 496,339 shs
• Average Volume: 706,002 shs
• Market Capitalization: $1.78 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.89
• Consensus Rating: Buy

AtriCure Stock Analysis - MarketRank™

AtriCure scored higher than 70% of companies evaluated by MarketBeat, and ranked 298th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

AtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

AtriCure has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AtriCure are expected to grow in the coming year, from ($0.60) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AtriCure is -46.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AtriCure is -46.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AtriCure has a P/B Ratio of 3.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.06% of the outstanding shares of AtriCure have been sold short.

Short Interest Ratio / Days to Cover

AtriCure has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AtriCure has recently decreased by 1.94%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AtriCure does not currently pay a dividend.

Dividend Growth

AtriCure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.06% of the outstanding shares of AtriCure have been sold short.

Short Interest Ratio / Days to Cover

AtriCure has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AtriCure has recently decreased by 1.94%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.88

News Sentiment

AtriCure has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for AtriCure this week, compared to 5 articles on an average week.

Search Interest

1 people have searched for ATRC on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added AtriCure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $175,050.00 in company stock.

Percentage Held by Insiders

Only 3.50% of the stock of AtriCure is held by insiders.

Percentage Held by Institutions

99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATRC Stock Analysis - Frequently Asked Questions

How have ATRC shares performed this year?

AtriCure's stock was trading at $30.56 on January 1st, 2025. Since then, ATRC shares have increased by 17.5% and is now trading at $35.90.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) announced its earnings results on Tuesday, July, 29th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.13. The firm's revenue for the quarter was up 17.1% compared to the same quarter last year.
Read the conference call transcript.

Does AtriCure have any subsidiaries?

AtriCure subsidiaries include these companies: SentreHEART.

Who are AtriCure's major shareholders?

AtriCure's top institutional investors include BNP PARIBAS ASSET MANAGEMENT Holding S.A. (1.52%), WCM Investment Management LLC (0.66%), Connor Clark & Lunn Investment Management Ltd. (0.53%) and Acadian Asset Management LLC (0.41%). Insiders that own company stock include Salvatore Privitera, Vinayak Doraiswamy, Justin J Noznesky, Karl S Dahlquist, Karen Prange and Maggie Yuen.
View institutional ownership trends.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:ATRC
• CIK: 1323885
• Web: www.atricure.com
• Phone: (513) 755-4100
• Fax: 513-755-4567
• Employees: 1,300
• Year Founded: 2000

Price Target and Rating

• Average Price Target for AtriCure: $50.89
• High Price Target: $60.00
• Low Price Target: $45.00
• Potential Upside/Downside: +41.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.70 million
• Net Margins: -7.27%
• Pretax Margin: -7.05%
• Return on Equity: -4.20%
• Return on Assets: -3.19%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 3.94
• Quick Ratio: 2.83

Sales & Book Value

• Annual Sales: $465.31 million
• Price / Sales: 3.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.35 per share
• Price / Book: 3.84

Miscellaneous

• Outstanding Shares: 49,700,000
• Free Float: 47,961,000
• Market Cap: $1.78 billion
• Optionable: Optionable
• Beta: 1.61